On the heels of FDA’s approval of the Wegovy Pill, Novo Noridsk announced that the oral GLP-1 is now available to patients across the U.S through prescription.

As of Monday January 5, 2026, patients will have access to the starter dose of the oral GLP-1, 1.5 mg, with additional strengths reported to be released by the end of the week.¹

The Wegovy (semaglutide) pill is the first oral GLP-1 medicine for obesity in the U.S. and is approved to be used with a reduced calorie diet along with increased physical activity for adults with obesity, or who are overweight and also have weight-related medical problems, to help them lose weight and keep it off.¹

It is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.

FDA’s approval of the Wegovy pill is based on the results gathered from the OASIS 4 Phase III clinical trial, a 64-week medical study including 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes.

Results from the OASIS 4 trial displayed that patients administered with the Wegovy pill once a day along with a reduced calorie diet and exercise achieved an average weight loss of 13.6%, compared to just 2.4% with placebo.¹

"We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment," said Ed Cinca, senior vice president, marketing & patient solutions at Novo Nordisk.”

How much does the Wegovy Pill cost?

Starting Monday January 5^th, the Wegovy Pill will be available to all eligible patients with multiple affordability options, including self-pay patients starting at a price of $149-per-month for the starting dose of 1.5 mg.¹ Until April 15, 2026, the 4 mg dose will be available to patients for a price of $149 per month then will jump to $199 per month, with the highest doses of the Wegovy pill set to be available for $299.¹

Commercially insured patients are expected to pay as little as $25 per month with the Wegovy savings offer according to Novo Nordisk.

“Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care, " said Cinca.

Sources

1. Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk January 5, 2026 https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html
2. Starter Dose of Wegovy now Available as a Daily Pill Instead of Weekly Injection CNN Health January 5, 2026https://www.cnn.com/2026/01/05/health/wegovy-pill-weight-loss